Relevant bibliographies by topics / CD20 antibodies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'CD20 antibodies'

Author: Grafiati
Published: 11 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'CD20 antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "CD20 antibodies"

1

Galtseva, I. V., Yu A. Tsoy, A. E. Grachev, et al. "Multicolor flow cytometry in the diagnosis of Waldenstrom macroglobulinemia." Oncohematology 20, no. 1 (2025): 128–38. https://doi.org/10.17650/1818-8346-2025-20-1-128-138.

Full text
Abstract:
Waldenstrom macroglobulinemia is a lymphoplasmacytic lymphoma, the morphological substrates of which are b‑lymphocytes, proplasmocytes, and plasma cells. The world Health Organization recommends multicolor flow cytometry with analysis of markers such as IgM, Cd19, Cd20, Cd22, Cd25, Cd10, Cd23, Cd103, Cd138, for diagnosing this disease. Based on international and our own experience, we recommend that tumor b‑lymphocytes and plasma cells be analyzed separately for the diagnosis of waldenstrom macroglobulinemia, since the immunophenotypic profile of these populations differs. In diagnostics, this
APA, Harvard, Vancouver, ISO, and other styles
2

Fuh, Franklin, Reina Fuji, Kirsten A. Poon, et al. "Pharmacodynamic Effects of Administration of Maytansine Conjugated Anti-CD22 Monoclonal Antibodies to Cynomolgus Monkeys." Blood 112, no. 11 (2008): 4996. http://dx.doi.org/10.1182/blood.v112.11.4996.4996.

Full text
Abstract:
Abstract CD22 is a B cell-specific glycoprotein expressed on the cell surface of all mature B cells. A candidate therapeutic anti-CD22 antibody, 10F4v3, was conjugated to the anti-mitotic agent maytansine (10F4v3-DM1). DM1 disrupts cellular mitosis through inhibition of tubulin polymerization when internalized into cells. The anti-CD22 DM1 conjugate was shown to have significant potency in preclinical efficacy models of NHL. In order to further characterize this antibody-drug conjugate in preclinical studies, we first evaluated the binding characteristics of the 10F4v3 to peripheral blood B ce
APA, Harvard, Vancouver, ISO, and other styles
3

Duperray, C., J. M. Boiron, C. Boucheix, et al. "The CD24 antigen discriminates between pre-B and B cells in human bone marrow." Journal of Immunology 145, no. 11 (1990): 3678–83. http://dx.doi.org/10.4049/jimmunol.145.11.3678.

Full text
Abstract:
Abstract When bone marrow (BM) lymphoid cells from 12 adult healthy donors were labeled by CD24 antibodies and analyzed by flow cytometry, two positive populations of cells were demonstrated in each sample (by a separated bimodal specific immunofluorescence). One population had intermediate CD24-Ag density (termed CD24+ cells) whereas the other had high CD24-Ag density (termed CD24(2+) cells). CD24+ cells represented 5.8 +/- 2.7% of the total lymphoid BM cells and CD24(2+) cells 5.6 +/- 2.5%. Using dual fluorescence analysis on eight samples, all CD24+ cells expressed the CD21 and CD37 mature
APA, Harvard, Vancouver, ISO, and other styles
4

Rymkiewicz, Grzegorz, Renata Woroniecka, Katarzyna Blachnio, Barbara Pienkowska-Grela, and Jan Walewski. "Flow Cytometry and Fluorescence In Situ Hybridization Are Methods of Choice for Routine Diagnosis of Mantle Cell Lymphoma." Blood 106, no. 11 (2005): 4659. http://dx.doi.org/10.1182/blood.v106.11.4659.4659.

Full text
Abstract:
Abstract Mantle cell lymphoma (MCL) is a distinct clinicopathologic entity, characterized by expansion of lymphocytes with co-expression of CD5 and CD20 and frequent t(11;14) translocation. MCL and its morphological variants are frequently confused with other lymphoma subtypes. The aim of this study was to analyze a contribution of histopathology (HP), immunohistochemistry (IHC), flow cytometry (FCM) and cytogenetic analysis with fluorescence in situ hybridization (FISH) to ultimate diagnosis of MCL. We identified 66 pts diagnosed with MCL either by use of HP/IHC or/and FCM. Initial diagnosis
APA, Harvard, Vancouver, ISO, and other styles
5

Lones, Mark, and Ivan Kirov. "Cell Surface Targets for Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents." Blood 104, no. 11 (2004): 4544. http://dx.doi.org/10.1182/blood.v104.11.4544.4544.

Full text
Abstract:
Abstract Recently, monoclonal antibodies have become available for treatment of lymphoid neoplasms in adults, but have not been studied in children and adolescents. These monoclonal antibodies are directed against cell surface antigens CD20 (Rituximab, Ibritumomab-Tiuxetan, Tositumomab), CD22 (Epratuzumab), CD52 (CAMPATH-1H), HLA-DR Beta-chain (Hu1D10), CD23 (IDEC-152), and CD33 (Gemtuzumab Ozogamicin). The objective of this study is to identify cell surface targets eligible for monoclonal antibody therapy in lymphoid neoplasms of children and adolescents. This is a retrospective analysis of l
APA, Harvard, Vancouver, ISO, and other styles
6

Paiva, Aldair Sousa, Alessandra Suelen Jardim Silva, Victor lima Soares, et al. "Importance of Flow Cytometry in the Differential Diagnosis of Hairy Cell Leukemia in the State of Rio Grande Do Norte, Brazil." Blood 136, Supplement 1 (2020): 14–15. http://dx.doi.org/10.1182/blood-2020-143225.

Full text
Abstract:
Introduction:Hairy Cell Leukemia (HCL) is a B-cell non-Hodgkin's Lymphoma (B-NHL) representing about 2% of chronic leukemias, is manifested in adults with an average age of 55 years old or more and the ratio of male: female is 5:1, being more common among white people. It is characterized by the presence of neoplastic lymphocytes with cytoplasmic projections (villous cells), a characteristic commonly observed in other DLPCs such as variant HCL (HCL-v) and splenic villous cell lymphoma (SVCL), being the immunophenotyping by flow cytometry determinant in the differential diagnosis of these neopl
APA, Harvard, Vancouver, ISO, and other styles
7

Geisler, CH, JK Larsen, NE Hansen, et al. "Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia." Blood 78, no. 7 (1991): 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.1795.

Full text
Abstract:
Abstract Blood mononuclear cells from 540 newly diagnosed, unselected patients with B-cell chronic lymphocytic leukemia (CLL) were examined by immunofluorescence flow cytometry for a panel of surface membrane markers, including IgM and IgD, the monoclonal antibodies anti-CD3, -5, -20, -21, -22, -FMC7, and, for the final 125 patients, anti-CD23. There were 503 CD5+ and 37 CD5- cases. In the CD5+ cases, the cells typically expressed IgM, IgD, CD20, CD21, CD22, and CD23. In univariate analysis, age, clinical stage, IgM-fluorescence intensity, CD23, and FMC7 had significant prognostic importance,
APA, Harvard, Vancouver, ISO, and other styles
8

Geisler, CH, JK Larsen, NE Hansen, et al. "Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia." Blood 78, no. 7 (1991): 1795–802. http://dx.doi.org/10.1182/blood.v78.7.1795.bloodjournal7871795.

Full text
Abstract:
Blood mononuclear cells from 540 newly diagnosed, unselected patients with B-cell chronic lymphocytic leukemia (CLL) were examined by immunofluorescence flow cytometry for a panel of surface membrane markers, including IgM and IgD, the monoclonal antibodies anti-CD3, -5, -20, -21, -22, -FMC7, and, for the final 125 patients, anti-CD23. There were 503 CD5+ and 37 CD5- cases. In the CD5+ cases, the cells typically expressed IgM, IgD, CD20, CD21, CD22, and CD23. In univariate analysis, age, clinical stage, IgM-fluorescence intensity, CD23, and FMC7 had significant prognostic importance, with high
APA, Harvard, Vancouver, ISO, and other styles
9

Weitzman, James, Monica Betancur, Laurent Boissel, Arthur P. Rabinowitz, and Hans Klingemann. "Variable Contribution of Different Monocloncal Antibodies to NK Cell-Mediated ADCC Against Primary CLL Cells." Blood 110, no. 11 (2007): 4715. http://dx.doi.org/10.1182/blood.v110.11.4715.4715.

Full text
Abstract:
Abstract Chronic Lymphocytic Leukemia (CLL) is characterized by the expression of the B-cell antigens CD19, 20 and 22, along with CD5 and CD23. These antigens make the malignant cells an ideal target for monoclonal antibody (mAb) therapy. Although the mechanism of action of mAbs is complex and not fully understood, one well-described action is antibody-dependent cellular cytotoxicity (ADCC). Binding of mAb to its target surface antigen initiates cytotoxicity through the interaction of the Fc portion of the mAb with the Fc receptor (FcR) on natural killer (NK) cells. This triggers release of pe
APA, Harvard, Vancouver, ISO, and other styles
10

Qu, Zhengxing, David M. Goldenberg, Thomas M. Cardillo, Victoria Shi, Hans J. Hansen, and Chien-Hsing Chang. "Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action." Blood 111, no. 4 (2008): 2211–19. http://dx.doi.org/10.1182/blood-2007-08-110072.

Full text
Abstract:
Combination immunotherapy with anti-CD20 and anti-CD22 mAbs shows promising activity in non-Hodgkin lymphoma. Therefore, bispecific mAbs (bsAbs) were recombinantly constructed from veltuzumab (humanized anti-CD20) and epratuzumab (humanized anti-CD22) and evaluated in vitro and in vivo. While none of the parental mAbs alone or mixed had notable antiproliferative activity against Burkitt lymphoma cells when not cross-linked, the bsAbs [eg, anti-CD20 IgG-anti–CD22 (scFv)2] were inhibitory without cross-linking and synergistic with B-cell antigen (BCR)-mediated inhibition. The bsAbs demonstrated
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "CD20 antibodies"

1

Eve, Heather E. "Lenalidomide and the new-generation anti-CD20 antibodies in mantle cell lymphoma." Thesis, Exeter and Plymouth Peninsula Medical School, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.573119.

Full text
Abstract:
Lenalidomide is a second-generation immunomodulatory drug with clinical activity in mantle cell lymphoma (MCL). In vitro work shows that lenalidomide enhances NK-mediated cytotoxicity against MCL yet the significance of this in vivo remains unproven. Since NK cells are key effectors of antibody-dependent cellular cytotoxicity (ADCC), there is a clear rationale for combining lenalidomide with monoclonal antibodies. However, one concern regarding this is the potential for lenalidomide to downregulate target antigen expression on malignant B Iymphocytes. This thesis presents phase II clinical tri
APA, Harvard, Vancouver, ISO, and other styles
2

Walshe, Claire Anne. "Signalling cascades induced by type I and II anti-CD20 monoclonal antibodies." Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436973.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shan, Daming. "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies /." Thesis, Connect to this title online; UW restricted, 1998. http://hdl.handle.net/1773/5682.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

DIAS, CARLA R. de B. R. "Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re." reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0<br>Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0<br>Tese (Doutoramento)<br>IPEN/T<br>Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
5

Nolan, David Francis Luke. "The synergistic interaction between CD20 monoclonal antibodies and histone deacetylase inhibitors in B cell Non Hodgkin's Lymphoma." Thesis, University of Southampton, 2010. https://eprints.soton.ac.uk/162661/.

Full text
Abstract:
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomas have resulted in targeted therapies becoming incorporated into treatment paradigms. The anti-CD20 monoclonal antibody, Rituximab, has resulted in dramatic improvements in survival for patients with B cell Non Hodgkin’s lymphoma. Histone deacetylase inhibitors are a novel class of anti cancer agents targeting epigenetic regulation. This thesis addresses the interaction between histone deacetylase inhibitors and anti-CD20 monoclonal antibodies, including Rituximab, both in vitro and in vivo. The initial approach identified sy
APA, Harvard, Vancouver, ISO, and other styles
6

Reslan, Lina. "Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia." Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10346/document.

Full text
Abstract:
CD20 est une cible thérapeutique validée pour l’immunothérapie des néoplasmes lymphoïdesdes cellules B, incluant la Leucémie Lymphoïde Chronique (LLC). Nous avons comparé les effets de rituximab et de GA101 (nouvel anticorps anti-CD20) contre les cellules LLC fraiches in vitro. Le marquage avec Annexine V a démontré une induction de l’apoptose après l’exposition au rituximab et GA101.Contrairement au rituximab, GA101 induisait une réduction du potentiel transmembranaire mitochondrial, uneffet qui peut être partiellement inhibé par la cyclosporine A et qui est partiellement caspase-dépendant. G
APA, Harvard, Vancouver, ISO, and other styles
7

Spasevska, Ivana. "The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1304/document.

Full text
Abstract:
Les anticorps monoclonaux (AcM) anti-CD20 sont essentiels pour le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique (LLC). Les AcM agissent soit en activant directement la signalisation apoptotique dans les cellules cibles, soit via le système immunitaire. Dans une étude préclinique, nous avons montré que le traitement avec AcM anti-CD20, rituximab et GA101, induit l'expression de la protéine early growth response 1 (EGR-1) (Dalle et al., 2011). EGR-1 est un facteur de transcription régulé par le calcium (Ca2+) et CD20 est impliqué dans la régulation du flux calcique
APA, Harvard, Vancouver, ISO, and other styles
8

AKANJI, AKINKUNMI G. "Estudo de marcação com iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma nao-hodgkin." reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11488.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:52:27Z (GMT). No. of bitstreams: 0<br>Made available in DSpace on 2014-10-09T14:01:38Z (GMT). No. of bitstreams: 0<br>Dissertação (Mestrado)<br>IPEN/D<br>Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP
APA, Harvard, Vancouver, ISO, and other styles
9

Nishida, Michio. "Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions." Kyoto University, 2008. http://hdl.handle.net/2433/124332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

AKANJI, AKINKUNMI G. "Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos." reponame:Repositório Institucional do IPEN, 2013. http://repositorio.ipen.br:8080/xmlui/handle/123456789/28021.

Full text
Abstract:
Submitted by Pedro Silva Filho (pfsilva@ipen.br) on 2017-11-17T17:17:04Z No. of bitstreams: 0<br>Made available in DSpace on 2017-11-17T17:17:04Z (GMT). No. of bitstreams: 0<br>Linfomas são cânceres que se iniciam a partir da transformação maligna de um linfócito no sistema linfático. Os linfomas são divididos em duas categorias principais: os linfomas de Hodgkin e todos os outros linfomas, denominados linfomas não-Hodgkin (LNH). Os pacientes com LNH são comumente tratados com radioterapia apenas ou combinada com quimioterapia utilizando-se de anticorpo monoclonal anti-CD20, principalmente o
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "CD20 antibodies"

1

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal. Elsevier Science & Technology, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cho, William Chi Shing. Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal. Elsevier Science & Technology Books, 2023.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dörner, Thomas, and Peter E. Lipsky. Cellular side of acquired immunity (B cells). Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0050.

Full text
Abstract:
B cells have gained interest in rheumatoid arthritis (RA) beyond being the precursors of antibody-producing plasma cells since they are also a broader component of the adaptive immune system. They are capable of functioning as antigen-presenting cells for T-cell activation and can produce an array of cytokines. Disturbances of peripheral B-cell homeostasis together with the formation of ectopic lymphoid neogenesis within the inflamed synovium appears to be a characteristic of patients with RA. Enhanced generation of memory B cells and autoreactive plasma cells producing IgM-RF and ACPA-IgG ant
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "CD20 antibodies"

1

Kozan, Esin Oguz, and Eyup Naci Tiftik. "Immunotherapy in Chronic Leukemias." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.7.

Full text
Abstract:
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative hematopoietic stem cell disorder. The most important immunotherapeutic drugs in the treatment of CML are tyrosine kinase inhibitors (TKI) and interferon. Chronic lymphocytic leukemia, another type of chronic leukemia, is one of the B cell chronic lymphoproliferative disorders. It is used in the treatment of three types of drug groups: anti-CD20 monoclonal antibodies, anti-CD19 monoclonal antibodies and bruton thyrosine kinase inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
2

Lindorfer, Margaret A., Joost M. Bakker, Paul W. H. I. Parren, and Ronald P. Taylor. "Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity." In Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klein, Christian, Marina Bacac, Pablo Umaña, and Michael Wenger. "Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma." In Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jacene, Heather A., and Richard L. Wahl. "Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”)." In Therapeutic Nuclear Medicine. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/174_2013_943.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Newton, Dianne L., Luke H. Stockwin, and Susanna M. Rybak. "Anti-CD22 Onconase: Preparation and Characterization." In Therapeutic Antibodies. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-554-1_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

van de Donk, Niels W. C. J., and Eugen Dhimolea. "Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies." In Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014. http://dx.doi.org/10.1002/9783527682423.ch49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Elluru, Sri Ramulu, Srini V. Kaveri, and Jagadeesh Bayry. "Regulation of Human Dendritic Cell Functions by Natural Anti-CD40 Antibodies." In Methods in Molecular Biology. Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0669-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Reinhold, D., T. Kähne, M. Täger, et al. "The Effect of Anti-CD26 Antibodies on DNA Synthesis and Cytokine Production (IL-2, IL-10 and IFN-γ) Depends on Enzymatic Activity of DP IV/CD26." In Advances in Experimental Medicine and Biology. Springer US, 1997. http://dx.doi.org/10.1007/978-1-4757-9613-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Turco, Maria Caterina, Mario De Felice, Soo Young Yang, Soldano Ferrone, and Salvatore Venuta. "Differential Modulation by Anti-HLA Class I Monoclonal Antibodies of T Cell Proliferation Induced via CD2 and CD3 Pathways." In Immunobiology of HLA. Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-662-39946-0_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ferrone, S., M. De Felice, M. C. Turco, L. Corbo, and S. Venuta. "Effect of Anti-HLA Class I Monoclonal Antibodies on the Proliferation of T Cells Induced by PHA-P. Comparison with the Effect on T Cell Activation via the CD2 and CD3 Pathways." In MHC + X. Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-74026-8_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "CD20 antibodies"

1

Hardwick, R. Alan, Bruce L. Levine, Carl H. June, et al. "Development of Closed Systems for Ex Vivo Cell Processing: Utility in Cell and Gene Therapy." In ASME 1997 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1997. http://dx.doi.org/10.1115/imece1997-1316.

Full text
Abstract:
Abstract Two examples are described in which cells were processed in a closed sterile fluid path by using custom-designed instruments, plastic bags and tubing sets, and a sterile connection device. In the first example, nucleated blood cells were collected from HIV+ patients. These cells were enriched for CD4+ cells and the CD4+ cells were expanded in the presence of immobilized CD3 and CD28 antibodies. The cells were then concentrated, washed, and re-infused. For the largest batches this resulted in 2.20 × 1010 cells with 86% viability and a CD4+ cell purity ≥ 95%. In two out of three re-infu
APA, Harvard, Vancouver, ISO, and other styles
2

Tent, Michiel. "Chronic active MS lesions respond poorly to anti-CD20 antibodies." In ECTRIMS Congress 2022, edited by Hans-Peter Hartung. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/45da9aa4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moskalets, O. V. "The incidence of anti-rituximab antibodies in patients with chronic lymphocytic leukemia." In Global science. Development and novelty. L-Journal, 2020. http://dx.doi.org/10.18411/gsdn-25-12-2020-05.

Full text
Abstract:
The aim of this study was to investigate the incidence of antibodies to rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies were determined in patients with B-chronic lymphocytic leukemia (newly diagnosed and resistant / recurrent forms, previously treated by rituximab) and healthy controls. Results: none of the patients with newly diagnosed disease have antibodies to rituximab. Positive results were recorded in 8 (33%) patients who received rituximab earlier.
APA, Harvard, Vancouver, ISO, and other styles
4

Xu, Wei, Johannes Sam, Mario Perro, et al. "Abstract 957: Design of CD19-4-1BBL, a novel CD19-targeted 4-1BB ligand for combination therapy with CD20 T-cell bispecific antibodies and CD20 antibodies." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-957.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moskalets, O. V. "Anti-rituximab antibodies in refractory / relapsing cases of chronic lymphocytic leukemia." In General question of world science. L-Journal, 2020. http://dx.doi.org/10.18411/gq-30-11-2020-02.

Full text
Abstract:
Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, is widley used for treatment of lymphomas, rheumatologic diseases and other – 8 – General question of world science disorders. It is known that many monoclonal antibodies such as rituximab can elicit anti-drug antibodies, which may interfere with therapeutic response. The aim of this study was to investigate the incidence of antibodies to rituximab in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies was determined in blood serum of patients with B-chronic lymphocy
APA, Harvard, Vancouver, ISO, and other styles
6

Martin de Frémont, G., H. Chabrolles, A. Mirand, et al. "POS0700 SEVERE ENTEROVIRUS INFECTIONS IN PATIENTS WITH AUTOIMMUNE DISEASES RECEIVING ANTI-CD20 MONOCLONAL ANTIBODIES." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.3005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gupta, Pankaj, Edmund A. Rossi, David M. Goldenberg, and Chien-Hsing Chang. "Abstract 4572: Heterodimerization of CD74 and CD20 by two hexavalent, bispecific, anti-CD20/CD74 antibodies leads to potent cytotoxicity in mantle cell lymphoma." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Spasevska, Ivana, Jade Villé, Kamel Chettab, Eva-Laure Matera, and Charles Dumontet. "Abstract 4594: Induction of apoptosis by anti-CD20 antibodies requires the induction of EGR-1 and calcium influx." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pyrzynska, Beata, Abdessamad Zerrouqi, Michal Dwojak, et al. "Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 1-4, 2017; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zerrouqi, Abdessamad, Beata Pyrzynska, Michal Dwojak, et al. "Abstract B27: B-cell lymphoma response to anti-CD20 antibodies based therapies is tightly modulated by FOXO1-mediated MS4A1 gene transcription." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 1-4, 2017; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b27.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "CD20 antibodies"

1

Wu, Xin. The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0075.

Full text
Abstract:
Review question / Objective: The objectives of this systematic review were to evaluate the efficacy and safety of the three existing anti-CD20 antibodies for the treatment of relapsing multiple sclerosis and to aid clinicians in choosing medications. Eligibility criteria: We set the inclusion criteria as follows: (1) study type: RCT; (2) language restriction: only available in English; (3) participants: patients ≥18 years of age diagnosed with relapsing MS, whether with a relapsing–remitting course or a secondary progressive course; (4) intervention: anti-CD20 antibody treatments including ocr
APA, Harvard, Vancouver, ISO, and other styles
2

Lin, Zhijuan, Xing Chen, Long Liu, Zhifeng Li, and Bing Xu. Chemo-Free Treatments in Relapsed and/or Refractory Follicular Lymphoma: A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.11.0111.

Full text
Abstract:
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the internationa
APA, Harvard, Vancouver, ISO, and other styles
3

Palaga, Tanapat, Nattiya Hirankarn, and Hathaipat Phuwapirom. Level of IL-17 in Thai SLE patients. Chulalongkorn University, 2009. https://doi.org/10.58837/chula.res.2009.30.

Full text
Abstract:
Systemic Lupus Erythematosus (SLE) is an autoimmune disorder which affects various systems. Currently, the etiology of this disease has not been fully elucidated. One of potential causes which may play an important role is the defects in cytokine network and the functions of T lymphocytes. Previously, it was reported that SLE patients showed elevated elevated level of various cytokines such as IL-1β IL-6 IL-23. The aim of this study was to investigate the level of cytokine IL-17 which could be produced by various cell types including T lymphocytes CD4+ T lymphocytes mainly producing IL-17 form
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'CD20 antibodies' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography